期刊文献+

杭州地区19家医院2004~2008年质子泵抑制剂利用分析 被引量:13

Utilization of Proton Pump Inhibitors in 19 Hospitals of Hangzhou Area during the Period of 2004~2008
原文传递
导出
摘要 目的:评价杭州地区19家医院质子泵抑制剂的应用情况及趋势,为该类药物的研发、生产、销售和临床应用提供参考。方法:统计杭州地区19家医院2004~2008年质子泵抑制剂的销售金额、用药频度和限定日费用。结果:5年来该地区医院质子泵抑制剂的销售金额、用药频度均大幅增长,口服奥美拉唑(包括胶囊和片剂)的用量最大、增长平稳,新一代质子泵抑制剂雷贝拉唑和埃索美拉唑用量增长迅速。结论:质子泵抑制剂是一类很有发展潜力的药物,奥美拉唑作为相对成熟的质子泵抑制剂,在临床应用仍最为广泛。 OBJECTIVE:To investigate situation and trend of proton pump inhibitors in 19 hospital of Hangzhou area and to provide reference for the research,production,sales and clinical application of this kind of drugs. METHODS:Utilization of proton pump inhibitors in 19 hospital of Hangzhou area during the period of 2004~2008 were analyzed statistically in respect of consumption sum,DDDs and DDC. RESULTS:Both consumption sum and DDDs of proton pump inhibitors increased quickly in recent five years. Amount of oral omeprazole(capsule and tablet)was the greatest among those categories and increased steadily. Amount of rabeprazole and esomeprazole as new type of proton pump inhibitors increased rapidly. CONCLUSION:Proton pump inhibitors have great potential for development. Omeprazole are widely used in the clinic as mature proton pump inhibitors.
作者 严玲
出处 《中国药房》 CAS CSCD 北大核心 2010年第22期2037-2039,共3页 China Pharmacy
关键词 质子泵抑制剂 用药分析 限定日剂量 Proton pump inhibitors Analysis of drug use DDDs
  • 相关文献

参考文献5

二级参考文献39

  • 1谭跃.洛赛克治疗上消化道出血[J].中国新药杂志,1994,3(2):15-17. 被引量:13
  • 2赵飞,张建中,曾浔.新视角——质子泵抑制剂及其体外抑制幽门螺杆菌作用研究进展[J].中国全科医学,2005,8(11):936-938. 被引量:24
  • 3裴瑛,王宝恩,陈寿坡,吴铁镛.兰索拉唑治疗十二指肠溃疡的临床观察[J].中华内科杂志,1995,34(9):606-608. 被引量:23
  • 4上海泮托拉唑协作组.泮托拉唑治疗消化性溃疡疗效观察[J].中华消化杂志,2001,21(2):22-22.
  • 5黄跃.奥美拉唑的不良反应[J].中国新药与临床杂志,1993,2(4):44-44.
  • 6 Williams MP,Pounder RE.Review article∶ the pharmacology of rabeprazole[J].Aliment PharmacolTher,1999,13(Suppl 3)∶S3~S10
  • 7 Hongo M,Kimpara T,Moriyama S,et al.Effect of rabeprazole(E3810),a novel protonpump inhibitor,nintragastric pH in healthy volunteers[J].Tohodu J Exp Med,1998,186(1)∶43~45
  • 8 Hirai M, Azuma T, Ito S,et al.A proton pump inhibitor, E3810, has antibacterialactivity through binding to Helicobacter pylori[J].J Gastroenterol,1995 ,30(4)∶461~464
  • 9 Swan SK, Hoyumpa AM, Merritt GJ.Review article∶ the pharmacokinetics ofrabeprazole in health and disease[J].Aliment Pharmacol Ther,1999, 13 (Suppl3)∶S11~S17
  • 10 Yasuda S, Ohnishi A, Ogawa T,et al.Pharmacokinetic properties of E3810, a newproton pump inhibitor,in healthy malevolunteers[J].Int J Clin Pharmacol Ther,1994,32(9)∶466~473

共引文献91

同被引文献86

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部